Item 5.02. Departure of Directors or Certain Officers;
Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective December 10, 2018, James A. Joyce resigned from his
position as a director and Chief Executive Officer of Aethlon Medical, Inc. (the “Company”). In connection with Mr.
Joyce’s resignation, effective December 10, 2018, the Board of Directors of the Company (the “Board”), upon approval
of the Compensation Committee of the Board, appointed Timothy C. Rodell, M.D., FCCP, 67, to serve as the Company’s Interim
Chief Executive Officer and, upon recommendation of the Nominating and Governance Committee of the Board, as a member of the Board.
Prior to joining the Company, Dr. Rodell served as President,
Chief Executive Officer and a Director of GlobeImmune, Inc., a public company developing immunotherapeutics for cancer, hepatitis
and other viral diseases, from April 2002 to November 2016, and as a Director and consultant to GlobeImmune, Inc. from November
2016 to present. Dr. Rodell has been a managing partner at SMG, Inc., a company that provides pharmaceutical product evaluation
and development, clinical and regulatory strategy, and evaluation of technology services for financial institutions, from 1999
to present. From 1999 to February 2002, Dr. Rodell was President, Chief Executive Officer and a Director of RxKinetix, Inc., a
private drug delivery company. Previously Dr. Rodell held senior management positions at OXIS International, Inc. and Cortech,
Inc. Dr. Rodell holds an M.D. from the University of North Carolina, Chapel Hill and is board certified in Internal Medicine and
Pulmonary Medicine. The Board believes that Dr. Rodell’s clinical background and extensive management experience in the biotechnology
industry, qualify him to serve on the Board.
In connection with Dr. Rodell’s appointment, the Company
entered into an employment agreement with Dr. Rodell that governs the terms of his employment with the Company. Among other things,
the employment agreement provides for (i) an annual base salary of $390,000, (ii) at the sole discretion of the Committee or the
Board, an annual target cash performance bonus, and (iv) an option to purchase 552,625 shares of the Company’s common stock,
at an exercise price equal to the fair market value on the date of grant, which will vest over a four-year period, with 25% vesting
on the one-year anniversary of the commencement of employment and the remainder vesting monthly thereafter in equal increments
for 36 months, subject to acceleration of vesting in the event of a change in control (as defined in the employment agreement).
In addition, in the event of a strategic transaction, as defined in the employment agreement, completed within two years of Dr.
Rodell’s commencement of employment with the Company, he will receive a cash bonus equal to 50% of his then annual base salary
and an additional equity grant such that Dr. Rodell’s equity interest in the Company is then equal to three percent. The
option will be subject to standard four-year vesting, subject to full vesting if Dr. Rodell is terminated in connection with the
strategic transaction.
Dr. Rodell also entered into the Company’s standard form
of indemnification agreement for its directors and executive officers.
There are no family relationships between Dr. Rodell and any
of the Company’s current or former directors or executive officers. Dr. Rodell is not a party to any transaction that would
require disclosure under Item 404(a) of Regulation S-K promulgated under the Securities Act of 1933.
On December 13, the Company issued a press release announcing
Dr. Rodell’s appointment. A copy of the press release is attached hereto as Exhibit 99.1.
On December 12, 2018, the Board approved an employment agreement
with James B. Frakes, the Company’s Chief Financial Officer and Vice President, Finance, providing for continuation of his
annual base salary of $260,000. In addition, the agreement provides that Mr. Frakes is eligible for an annual cash performance
bonus for each year. Whether Mr. Frakes receives an annual bonus for any given year, and the amount of any such annual bonus, will
be determined in the discretion of the Board (or the Compensation Committee thereof). The agreement also provides that if Mr. Frakes’
employment is terminated by the Company without cause, or if he resigns for good reason (each as defined in the agreement), then
Mr. Frakes will be entitled under his agreement to continue to receive his annual base salary and payment of premiums for continuation
of healthcare benefits for a period of 12 months following such termination.
On December 12, 2018, Rodney S. Kenley resigned from the Board
of Directors of the Company.